Executive Director Agilent Technologies Padraig McDonnell Sale $ 286,650 on Investing.com
The sale was carried out in accordance with the 10B5-1 rule, which allows insiders to set up a predetermined sales schedule to avoid potential conflict of interest. This plan was adopted by McDonnell on March 8, 2024. Investment Subscribers can access 15+ additional insights into Agilent’s measuring values of assessment and performance, including a detailed analysis of the insider trading form and comprehensive research reports. Investment Subscribers can access 15+ additional insights into Agilent’s measuring values of assessment and performance, including a detailed analysis of the insider trading form and comprehensive research reports.
The sale was conducted in accordance with the rule of 10B5-1 trading, which allows the company insiders to set a predetermined sales schedule to avoid potential conflict of interest. This plan was adopted by McDonnell on March 8, 2024.
In other recent news, Waters Corp (Nyse :). He experienced a drop in shares after the announcement of the US Department of Trade on New Export Controls on Biotechnology, citing national security concerns. These regulations could disrupt the sales and supply chains of the affected companies, including Waters Corp. In response to these movements, the Chinese embassy in Washington stated that China “firmly opposed the development, possession or use of the biological weapon of any country.”
Meanwhile, Agilent Technologies Inc (Nyse :). There was a focus of several notes of analysts. Stifel repeated the purchase assessment on Agilent’s stock, emphasizing the expansion and emphasis on operating margins and emphasis on PFAS testing as significant growth drivers. Similarly, Baird held its surveillance assessment on Agilent’s shares, noticing the dedication to the company productivity and efficiency as key drivers for future performance. Bernstein Socgen Group also held a rating of market effect for Agilent, after the event of the Day Investor.
Agilent informed the Q4 revenue in the amount of $ 1,701 billion for a fiscal year 2024 and provided year -round fiscal guidelines for 2025 revenue from $ 6.79 to $ 6.87 billion. The NO-GAAP EPS is expected to be between $ 5,54 and $ 5,61. Agilent also provided a certificate for in vitro Class C (IVDR) for its PD-L1 IHC 28-8 Pharmdx, a critical test used to determine the patient’s eligibility for specific cancer therapy. The company also underwent organizational transformation, dividing its structure into three groups: LDG, AMG and ACG. These are recent movements in Waters Corp. and Agilent Technologies Inc.
This article was generated with the support of AI and was examined by the editor. See our T&C for more information.
